U.S. flag

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

  • Publications
  • Account settings

Trending Articles

  • Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Welsh JA, et al. J Extracell Vesicles. 2024. PMID: 38326288 Free PMC article.
  • A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. Harrison SA, et al. N Engl J Med. 2024. PMID: 38324483
  • Clinical Characteristics, Outcomes, and Risk Factors for Mortality in Pregnant/Puerperal Women with COVID-19 Admitted to ICU in Turkey: A Multicenter, Retrospective Study from a Middle-Income Country. Baykara N, et al. J Intensive Care Med. 2024. PMID: 38320979
  • Microglia maintain structural integrity during fetal brain morphogenesis. Lawrence AR, et al. Cell. 2024. PMID: 38309258
  • Naturally occurring T cell mutations enhance engineered T cell therapies. Garcia J, et al. Nature. 2024. PMID: 38326614

Latest Literature

  • Am Heart J (1)
  • Am J Med (4)
  • Cell Metab (1)
  • Clin Infect Dis (1)
  • J Am Acad Dermatol (2)
  • J Biol Chem (11)
  • Nat Commun (28)
  • Nature (10)
  • Oncogene (1)

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

  • Why Portico
  • Core services
  • Preservation approach
  • Preservation step by step
  • Presentations and publications
  • Community involvement
  • Titles and collections
  • Triggered content

Request a holdings comparison

  • Facts and figures
  • Join Portico
  • For participants

https://journals.viamedica.pl/

Download this publisher's e-journal holdings (xlsx)

Portico provides a free  holdings comparison  service to compare a library’s journal or book holdings to the Portico archive.

Recent searches

Institutions, conferences, journals gallery.

40,000+ journal templates to choose from for your next paper

Flexible pricing plans that caters to everyone’s needs

Plagiarism check

Detect plagiarism early. Powered by Turnitin.

Journal Submission

Get accepted in top journals.

For Publishers

Streamline publishing process with automated workflows

Client Stories

Read what our clients have yielded with our products and services

Convert from Word

Word file to JATS XML, PMC XML, DOAJ XML and more

Convert from PDF

PDF file to SciELO XML, CrossRef XML and more

Convert from JATS XML

JATS XML to Redalyc XML, DataCite XML and more

Adhere to standard of all global publishing bodies

Compliance for medical journals in PubMed database

Generate standardized XML for SciELO indexed journals

Via Medica

Get your research paper 100% compliant with Via Medica Author guidelines. Choose any Journal below to get started.

medical research journal via medica

Journal Quality

Impact factor, show only open access, indexed database, journal count.

Journals listed from high to low quality

medical research journal via medica

Rheumatology Forum

Endocrinology, obesity and metabolic disorders, pomorski magazyn lekarski, acta angiologica, folia morphologica, forum dermatologicum, forum reumatologiczne - edukacja, hematology in clinical practice, international maritime health, medical research journal.

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

European Journal of Medical Research

Recruitment

Join the Editorial Board

We are recruiting Associate Editors to join our Editorial Board. Learn more about the role and how to apply here !

  • Most accessed

Decreased TLR7 expression was associated with airway eosinophilic inflammation and lung function in asthma: evidence from machine learning approaches and experimental validation

Authors: Kemin Yan and Yuxia Liang

Ultrasonographic assessment of renal microcirculation is a new vision for the treatment of intensive care unit associated acute kidney injury

Authors: Rongping Chen, Beijun Gao, Xinchen Wang, Hua Zhao, Xiaoting Wang and Dawei Liu

Causal relationships between delirium and Parkinson’s disease: a bidirectional two-sample Mendelian randomization study

Authors: Xiaoliang Bai, Anna Zhang, Qingbo Zhou and Hongli Wang

Downregulation of salusins alleviates hypertrophic cardiomyopathy via attenuating oxidative stress and autophagy

Authors: Jing-Yi Dang, Wei Zhang, Yi Chu, Jiang-Hong Chen, Zhao-Le Ji and Pin Feng

Autologous blood patch intraparenchymal injection reduces the incidence of pneumothorax and the need for chest tube placement following CT-guided lung biopsy: a systematic review and meta-analysis

Authors: Teng Li, Qiang Zhang, Wenjun Li and Yun Liu

Most recent articles RSS

View all articles

A review of neurological side effects of COVID-19 vaccination

Authors: Roya Hosseini and Nayere Askari

Face masks: benefits and risks during the COVID-19 crisis

Authors: Christiane Matuschek, Friedrich Moll, Heiner Fangerau, Johannes C. Fischer, Kurt Zänker, Martijn van Griensven, Marion Schneider, Detlef Kindgen-Milles, Wolfram Trudo Knoefel, Artur Lichtenberg, Balint Tamaskovics, Freddy Joel Djiepmo-Njanang, Wilfried Budach, Stefanie Corradini, Dieter Häussinger, Torsten Feldt…

Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: a systematic review and meta-analysis

Authors: Sulmaz Ghahramani, Reza Tabrizi, Kamran B. Lankarani, Seyyed Mohammad Amin Kashani, Shahla Rezaei, Nazanin Zeidi, Maryam Akbari, Seyed Taghi Heydari, Hamed Akbari, Peyman Nowrouzi-Sohrabi and Fariba Ahmadizar

Evaluation of preoperative anxiety and fear of anesthesia using APAIS score

Authors: Fatma Celik and Ipek S. Edipoglu

Impact of lockdown on COVID-19 prevalence and mortality during 2020 pandemic: observational analysis of 27 countries

Authors: Sultan Ayoub Meo, Abdulelah Adnan Abukhalaf, Ali Abdullah Alomar, Faris Jamal AlMutairi, Adnan Mahmood Usmani and David C. Klonoff

Most accessed articles RSS

Herpesviruses reactivation following COVID-19 vaccination: a systematic review and meta-analysis

Article of the Month: Herpesviruses reactivation following COVID-19 vaccination: a systematic review and meta-analysis

The reactivation of herpesviruses (HHV) in COVID-19 patients is evident in the literature. Several reports have been published regarding the reactivation of these viruses (HSV, VZV, EBV, and CMV) among those who got COVID-19 vaccines. This study aimed to review the current evidence to assess whether HHVs reactivation has any association with the prior administration of COVID-19 vaccines.

Aims and scope

European Journal of Medical Research publishes translational, preclinical and clinical research of international interest across all medical disciplines, enabling clinicians and other researchers to learn about developments and innovations within these disciplines and across the boundaries between disciplines. The journal also has a special focus on internal medicine, surgery, neurology, infectious diseases and intensive care medicine.

European Journal of Medical Research publishes high quality research and reviews and aims to ensure that the results of all well-conducted research are published, regardless of their outcome. 

10 Years at BMC timeline

Celebrating 10 Years at BMC!

In 2012, European Journal of Medical Research joined the portfolio of BMC journals, converting to the open access publishing model.

Join us in celebrating the occasion by looking back at the journal's milestone achievements! 

Spotlight: Featured review articles

Sign up to article alerts.

European Journal of Medical Research is published continuously online-only. We encourage you to sign up to receive free email alerts to keep up to date with all of the latest articles by registering here .

Altmetrics logo

Trending articles

Check out the most discussed articles from   European Journal of Medical Research  in the past 6 months!

About the Editors-in-Chief

New Content Item

Prof Bölke is a specialist in surgery, visceral surgery, emergency medicine, and has further training in surgical intensive care medicine and sports medicine. He works as a full time specialist in radiation oncology at the University of Düsseldorf. Since 2010, Prof Bölke has been a senior physician at the Clinic for Radiation Oncology at the University Hospital in Düsseldorf. He has been a professor for radiation oncology at the University of Düsseldorf since 2012. He is an author of more than 185 papers in PubMed.

medical research journal via medica

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

  • Publications
  • Account settings
  • Advanced Search
  • Journal List
  • J Multidiscip Healthc
  • PMC10239248

Using ChatGPT in Medical Research: Current Status and Future Directions

Suebsarn ruksakulpiwat.

1 Department of Medical Nursing, Faculty of Nursing, Mahidol University, Bangkok, Thailand

Ayanesh Kumar

2 School of Medicine, Case Western Reserve University, Cleveland, OH, USA

Anuoluwapo Ajibade

3 College of Art and Science, Department of Anthropology, Case Western Reserve University, Cleveland, OH, USA

This review aims to evaluate the current evidence on the use of the Generative Pre-trained Transformer (ChatGPT) in medical research, including but not limited to treatment, diagnosis, or medication provision.

This review follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We searched Google Scholar, Web of Science, PubMed, and Medline to identify studies published between 2022 and 2023 that aimed to utilize ChatGPT in medical research. All identified references were stored in EndNote.

We initially identified 114 articles, out of which six studies met the inclusion and exclusion criteria for full-text screening. Among the six studies, two focused on drug development (33.33%), two on literature review writing (33.33%), and one each on medical report improvement, provision of medical information, improving research conduct, data analysis, and personalized medicine (16.67% each).

ChatGPT has the potential to revolutionize medical research in various ways. However, its accuracy, originality, academic integrity, and ethical issues must be thoroughly discussed and improved before its widespread implementation in clinical research and medical practice.

Introduction

Artificial intelligence, or AI, has been described as a branch of computer science that focuses on creating intelligent machines that can think and act like humans. 1 AI makes decisions by learning from its environment and the information they obtain. 1 There is various type of AI, including machine learning, an algorithm that learns from data and makes a prediction. 1 , 2 Another type of AI is Natural Language Processing (NLP) which uses algorithms to understand and generate human-like conversations. 3 Recently, AI has been utilized in various ways, such as medical diagnosis, 4 the Internet of Things, 5 and artificial intelligence of things. 6

Especially in healthcare, AI has been beginning to be applied and shows the potential to transform many aspects of patient care and administrative processes within providers or pharmaceutical organizations. 2 A study from Davenport & Kalakota described the potential for AI in healthcare. The author suggested that healthcare providers and life sciences companies already use several types of AI. The fundamental application categories are diagnosis and treatment recommendations, patient engagement and adherence, and administrative activities. 2 A recent systematic review aimed to evaluate the existing evidence of a machine learning-based classification system that stratifies patients with stroke. The result found that machine learning models have the potential to help healthcare providers with stroke diagnoses that can lead to early treatment and improve patient outcomes. 7

Generative Pre-trained Transformer, or ChatGPT, an NLP system, is a chatbot launched by OpenAI in November 2022. It was designed to generate human-like conversations by understanding the context of a conversation and generating appropriate responses. 8 , 9 ChatGPT has several features that make it a powerful NLP system. It can understand the context of a conversation and generate appropriate responses in different styles, such as formal, informal, and humorous. 9 There is a debate about using ChatGPT in medical research, and a potential concern has been noted. For example, privacy and security. In medical research, AI systems depend on access to large amounts of private data, such as medical records. The data could be accessed by unauthorized parties and used for nefarious purposes if the data is not adequately protected and secured. 10 In addition, misuse and over-reliance is other significant concern that must be noted. Although AI systems like ChatGPT can be compelling, they could be better. Medical professionals may over-rely on AI systems and trust their decisions without adequately considering the limitations and potential errors of the technology. 10

This review aims to evaluate the current evidence related to the use of ChatGPT in medical research, including its potential to provide treatment, diagnosis, and medication. Although ChatGPT’s use in healthcare is still in its early stages, there is a need for sufficient prior research on the concept, research fields, and application cases. Therefore, this review seeks to provide insights into the current trends of utilizing this technology in medical research and offer suggestions for future research.

Identify Relevant Studies

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines 11 were used to guide the identification, screening, exclusion, and inclusion of articles in this review. Four electronic databases (Google Scholar, Web of Science, PubMed, and Medline) were searched on January 21, 2023, at 9:26 PM EST to identify articles published between 2022 and 2023 that were related to or aimed to utilize ChatGPT in medical research. The search terms “ChatGPT” AND “Chatbot” AND “Medical Research” were used. Additionally, the reference lists of the included studies were manually searched to obtain relevant studies, and all references were stored in EndNote. A flow diagram was created to present the results of the search and screening process, following the PRISMA guidelines.

Study Selection

The authors independently screened the titles and abstracts of the identified studies to determine their relevance. Subsequently, the full text of the selected articles was also assessed to ensure they met the inclusion criteria. These criteria were implemented to ensure that only studies relevant to the objective of the review were included. Similarly, exclusion criteria were used to eliminate literature unrelated to the review ( Table 1 ).

Inclusion and Exclusion Criteria

Data Extraction

The standardized chart for data extraction ( Supplementary Table 1 ) consisted of the following data for each study: Reference, Year, Country, Study Design, Sample size, Target population, Objective, Results (Utilize ChatGPT in medical research), Main result/key finding and Suggestions for future research.

Search Results

Initially, a total of 114 articles were identified. After running Endnote X8, no duplicates were found. Subsequently, 114 articles were screened based on their title and abstract using the inclusion and exclusion criteria, resulting in six articles eligible for full-text screening. During the full-text screening phase, no articles were excluded, and all six articles were included in the final analysis. Finally, the retrieval process was outlined using the PRISMA flow chart, as shown in Figure 1 .

An external file that holds a picture, illustration, etc.
Object name is JMDH-16-1513-g0001.jpg

PRISMA flow chart.

Description of Included Studies

Table 2 displays that of the six included studies, two were published in 2023 (33.33%), and four were published in 2022 (66.67%). The studies were mainly conducted in the USA and Germany, with two studies from each country (25% each). One study was conducted in each of the following countries: the Republic of Korea, Turkey, Spain, and Switzerland, each accounting for 12.5%. The most popular study design was literature review (n = 2, 33.33%), followed by case study (n = 1, 16.67%), editorial (n = 1, 16.67%), and perspective (n = 1, 16.67%). One study had a sample size of 15 (16.67%), while the rest did not specify the target population due to the study design (n = 5, 83.33%). Only one study focused on radiologists (16.67%), while the majority did not have a specific target population (n = 5, 83.33%).

The Characteristics of the Included Studies

Note : *The number of included studies.

Abbreviation : N/A, Not applicable.

Description of the Key Finding of Included Studies

Table 3 summarizes the key findings of the included studies. Two studies (33.33%) explored the use of ChatGPT in drug development. In comparison, another two studies (33.33%) examined its application in writing literature reviews. One study (16.67%) described using ChatGPT for medical report improvement, one for providing treatment, one for providing medical information, one for improving research conduction, one for data analysis, and one for personalized medicine.

Key Findings of Included Studies

This review summarizes the use of ChatGPT in medical research. Currently, this AI is primarily used in drug development, improving medical reports, providing treatment and medical information, writing literature reviews on health-related topics, improving research conduct, data analysis, and personalizing medicine. The discussion section details how ChatGPT was utilized in each area and how it could be implemented in future research.

Drug Development

Evidence shows the potential of using AI technology in new drug development. Mann used ChatGPT to discuss the role of AI in translational medicine. The result illustrated that AI algorithms could help speed up new drug development and treatment and identify the side effect and interactions. 17 In addition, a study by Blanco-Gonzalez et al discussed the benefits, challenges, and drawbacks of AI in drug discovery. It has shown that AI techniques, such as machine learning, can accelerate and improve drug development processes by enabling more efficient and accurate analysis of large amounts of data. 12 This is consistent with previous studies suggesting that AI has been found to improve the efficiency of the drug development process and successfully predict the efficacy of drug compounds with high accuracy. 18 , 19 Although AI is expected to significantly contribute to developing new medications in the following few years, limitations, including ethical issues, must be considered. Moreover, AI should be cautiously employed in science until it can be entrusted to produce reliable and accurate information. Also, it is crucial to carefully evaluate the information provided by AI tools such as ChatGPT and validate it using reliable sources.

Medical Report Improvement

Although ChatGPT is not explicitly developed for simplifying medical reports, it has surprisingly performed well. One of our included studies investigated the phenomenon that ChatGPT may be used to simplify radiology reports. This case study included 15 radiologists to provide the agreement in radiology reports generated by ChatGPT. 13 Overall, radiologists agreed that the simplified reports generated by ChatGPT were complete but had some errors, such as missed findings or unspecific locations. Accordingly, it may cause imprecision in the medical context, leading to an error in patient treatment and clinical decision-making. 13 A previous study discussing using AI for quality improvement in radiology also suggested that AI can provide more support, such as ensuring medical reports are accurate, readable, and helpful to patients and healthcare providers. 20 However, future research is still needed to validate the findings and further explore the possibilities of this new technology in the medical domain. In this case, ChatGPT may involve a simplified radiology report autogenerated alongside an original report, proofread by a radiologist, and corrected where needed.

Providing Treatment and Medical Information

The study by Kim determined the medical information and treatment options that ChatGPT can provide for shoulder impingement syndrome (SIS). 14 The result reveals that ChatGPT output provides essential and uncontroversial treatment options for SIS. However, more details and specific treatment options still need to be obtained through a medical professional. Thus, it will be difficult for non-experts to determine treatment options based on minimal depth in the information provided by ChatGPT since effective treatment varies greatly depending on an individual’s condition or degree of SIS. 14 Regarding medical information, ChatGPT considers exercise to be one of the critical factors in recovering from SIS and provides several exercise examples. However, the description of the posture and action of the pendulum exercise was inaccurate. 14 As Davenport & Kalakota suggested, AI will have a vital role in future healthcare offerings, particularly in treatment applications. However, accuracy and ethical issues must be addressed, making it challenging. 2 Similarly, ChatGPT can provide general and basic-level medical information. Nevertheless, future technological advancements in the medical field must pave the way to develop this AI to be more accurate and detailed in medical and treatment information.

Writing a Literature Review on a Health-Related Topic

Two included studies used ChatGPT to conduct the literature review on the medical-related topic. The literature review by Blanco-Gonzalez et al discussed the benefits, challenges, and drawbacks of AI in drug discovery and proposed possible strategies and approaches for overcoming barriers. This review was generated with the assistance of ChatGPT and verified by human authors. 12 Furthermore, Aydın & Karaarslan used ChatGPT to create a literature review of the theme of the application of digital twins in healthcare. 15 The result shows that the texts written by study authors tested a low level of plagiarism compared to ChatGPT. On the other hand, the paraphrased abstracts created by ChatGPT had very high levels of plagiarism. Also, ChatGPT does not produce original texts after paraphrasing. 15

A previous study aimed to determine whether ChatGPT can write a good boolean query for a systematic literature review search. The authors recommended that AI can follow complex instructions and generate exact queries, making it a valuable innovation for researchers conducting systematic reviews. 21 However, human editing and verification are still necessary to minimize plagiarism and errors. Additionally, utilizing ChatGPT to conduct research, such as a literature review, presents challenges due to originality and academic integrity issues. Therefore, researchers should carefully consider the policies of their research institutions and journals before using AI in their research writing.

Research Conduction, Data Analysis, and Personalized Medicine

Two studies included in the review report the potential of using ChatGPT in conducting research, data analysis, and personalized medicine. 16 , 17 Cahan & Treutlein illustrated how ChatGPT could assist practitioners across the broader stem cell research discipline, mainly by saving them time to conduct more research. 16 The author stated that ChatGPT could aid stem cell research in three ways: 1) the ability to process and analyze a large amount of cell-related data, 2) the optimization of stem cell culture conditions to allow for more efficient and controlled growth of stem cells, and 3) the creation of detailed models of stem cell behavior, helping researchers better understand how these cells respond to stimuli and how they can be manipulated for different purposes. 16

Likewise, Mann discussed the role of ChatGPT in translational medicine. The researcher suggested the following future directions for AI in translational medicine: 1) AI can be used in big data analysis, such as electronic medical records and genomic data, to help identify factors causing disease and predict patient outcomes; 2) AI can help develop personalized medicine that is tailored to the specific needs and characteristics of individual patients. 17 However, using ChatGPT in translational medicine presents challenges, such as: 1) algorithms can be biased and incomplete if the training data is biased and incomplete, potentially leading to inaccurate results that could impact patient care and outcomes; 2) AI may not fully understand the biological mechanisms of the human body system, resulting in limitations in providing factors contributing to disease and treatment; and 3) ethical implications of using AI, such as discrimination against certain populations or prioritizing specific groups, could lead to future healthcare inequalities and impact human life. 17

There are limitations to our review that need to be noted. Firstly, our search was limited to articles published in English between 2022 and 2023. Therefore, research published in other languages or outside of this timeframe may have been omitted, which could limit the generalizability and raise issues regarding the validity of the finding. Additionally, we focused specifically on the use of ChatGPT in medical research and did not include other potential applications of this technology in related fields. Finally, while we searched a range of databases, it is possible that some relevant studies were not captured by our search strategy.

Conclusion and Suggestions for Future Research

Over the recent years, ChatGPT has demonstrated its role in advancing the medical field, from supporting translational medicine and drug development with detailed and accurate data analysis to complementing medical practice and patient experience with improved medical reporting, diagnostics, and treatment plans. However, further work is required to enhance accuracy, originality, bias, and misuse and overcome issues pertaining to academic integrity, privacy, and ethics prior to the extensive application of this tool within research and clinical practice.

It is important to note that ChatGPT was not explicitly developed for application in research and medicine. As such, it lacks a much-needed depth in scientific and medical knowledge underlying mechanisms of disease and treatment. Yet, it has performed surprisingly well in providing basic-level support in research and clinical settings. This is a testament to its potential to revolutionize medicine and healthcare if further technological advancement of this model is made in conjunction with the medical field. For instance, future work must focus on training AI to develop an extensive understanding of the biological and medical sciences to improve the accuracy and depth of its analysis, diagnostics, and treatment plan generation. In addition, appropriate ethical guidelines, limitations, and authorizations must be placed on its use to prevent unauthorized use and protect privacy. Moreover, similar studies conducted in the future with improved models applied within research and clinical settings are required to track its progress. Finally, surveys of physicians’ and patients’ experiences and opinions may also aid in evaluating ChatGPT’s role in paving the way for a more seamless provider and patient care experience, respectively.

ChatGPT also has practical potential for enhancing patient care and treatment outcomes by providing medical information and facilitating communication between patients and healthcare providers. Academically, ChatGPT can advance understanding, identify new research questions, and improve data analysis and interpretation accuracy. Nevertheless, there are potential risks, such as the dissemination of inaccurate information and ethical concerns about informed consent, privacy, and data security. Therefore, researchers and healthcare providers must consider these factors when implementing ChatGPT-based interventions.

The authors report no conflicts of interest in this work.

Medica Journal

Medica Journal

Innovative education and research for a healthier north.

Free Medical Education, Research, Article  Made Accessible To Each & Every Aspiring Student & Professional.

-Our Vision-

To be a distinctive, preeminent research-intensive medical study platform, transforming health through discovery, lifelong learning, and patient-centered health care.

Pre-Medicine

It makes sense to assume that every pre-med student is destined to become a doctor, but that’s not always the case. Medica Journal will provide all types of content to build career smoothly.

Research & Development

Work directed towards the innovation, introduction, and improvement of medical study and processes. We’ve a leading virtual lab and communication base for R&D.

Article , Research & Case

The case study approach allows in-depth, multi-faceted explorations of complex issues in their real-life settings. Medica Journal is a free platform for publish all these.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • X (Twitter)
  • More Networks

ICHGCP

  • ICH GCP (De)
  • ICH GCP (En)
  • ICH GCP (Es)
  • ICH GCP (Fr)
  • ICH GCP (It)
  • ICH GCP (Pt)
  • ICH GCP (Ru)
  • AUSTRALIA (NHMRC)
  • JAPAN (PMDA)
  • US Clinical Trials Registry
  • EU Clinical Trials Registry
  • Pharmaceutical Companies
  • Clinical Research Labs
  • Service Companies
  • Clinical Research Events
  • Publications
  • Researchers

Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19 of Children at the Age of 12-17 Years Inclusive"

Double-blind, placebo-controlled, randomized study of tolerability, safety and immunogenicity of the inactivated whole-virion concentrated purified coronavirus vaccine, produced by fsbsi "chumakov federal scientific center for research and development of immune-and-biological products", of children at the age of 12-17 years inclusive", study overview, intervention / treatment.

  • Biological: Vaccine for intramuscular injection
  • Other: Placebo comparator (without active ingredient) for intramuscular injection

Detailed Description

Recruitment of volunteers will be competitive. A maximum of 450 children aged 12 to 17 years inclusive will be screened in the study, of which it is planned to include and randomize 300 children who meet the criteria for inclusion in the study and do not have non-inclusion criteria, data on which will be used for subsequent safety and immunogenicity analysis.

Group 1 - 150 volunteers who will be vaccinated with the Nobivac vaccine twice with an interval of 21 days intramuscularly.

Group 2 - 150 volunteers who will receive a placebo twice with an interval of 21 days intramuscularly.

In case of withdrawal of volunteers from the study, their replacement is not provided.

Enrollment (Anticipated)

Contacts and locations, study locations.

  • Kirov Regional State Budgetary Health Institution "Kirov Regional Children's Clinical Hospital"
  • FSBSI Chumakov FSC R&D IBP RAS
  • St. Petersburg State Budgetary Health Institution "Children's City Polyclinic No. 45 of the Nevsky District"
  • State Budgetary Health Institution of the Moscow Region "Elektrostal Central City Hospital"

Participation Criteria

Eligibility criteria, ages eligible for study, accepts healthy volunteers, genders eligible for study, description.

Inclusion Criteria:

  • Volunteers must meet the following inclusion criteria:

Type of participants • Healthy volunteers.

Age at the time of signing the Informed Consent

• from 12 to 17 years inclusive (12 years 0 months 0 days - 17 years 11 months 30 days).

Paul • Male or female.

Reproductive characteristics

  • For girls with a history of mensis - a negative pregnancy test and consent to adhere to adequate methods of contraception (use of contraceptives within a month after the second vaccination). Girls should use methods of contraception with a reliability of more than 90% (cervical caps with spermicide, diaphragms with spermicide, condoms, intrauterine spirals).
  • For young men capable of conception - consent to adhere to adequate methods of contraception (use of contraceptives within a month after the second vaccination). Young men and their sexual partners should use methods of contraception with a reliability of more than 90% (cervical caps with spermicide, diaphragms with spermicide, condoms, intrauterine spirals).

Research procedures

  • Written Informed consent of a volunteer (14 years and older) and one of the parents to participate in a clinical trial.
  • Volunteers who are able to fulfill Protocol requirements (i.e. answer phone calls, fill out a Self-observation Diary, come to control visits).

Non-inclusion criteria:

  • Volunteers cannot be included in the study if any of the following criteria are present:

SARS-CoV-2 infection

  • A case of established COVID-19 disease confirmed by PCR and/or ELISA in the last 6 months.
  • History of contacts with confirmed or suspected cases of SARS-CoV-2 infection within 14 days prior to vaccination.
  • Positive IgM or IgG to SARS-CoV-2 detected on Screening.
  • Positive PCR test for SARS-CoV-2 at Screening / before vaccination.

Diseases or medical conditions

  • Serious post-vaccination reaction (temperature above 40 C, hyperemia or edema more than 8 cm in diameter) or complication (collapse or shock-like condition that developed within 48 hours after vaccination; convulsions, accompanied or not accompanied by a feverish state) to any previous vaccination.
  • Burdened allergic history (anaphylactic shock, Quincke's edema, polymorphic exudative eczema, serum sickness in the anamnesis, hypersensitivity or allergic reactions to the introduction of any vaccines in the anamnesis, known allergic reactions to vaccine components, etc.).
  • Guillain-Barre syndrome (acute polyradiculitis) in the anamnesis.
  • The axillary temperature at the time of vaccination is more than 37.0 ° C.
  • Positive blood test for HIV, syphilis, hepatitis B/C.
  • Acute infectious diseases (recovery earl

Exclusion Criteria:

- • Withdrawal of Informed consent by a volunteer and/or a parent of a volunteer;

  • The volunteer was included in violation of the inclusion/non-inclusion criteria of the Protocol;
  • Availability of inclusion/non-inclusion criteria before vaccination;
  • Any condition of a volunteer that requires, in the reasoned opinion of a medical researcher, the withdrawal of a volunteer from the study;
  • The established fact of pregnancy before the second vaccination;
  • Taking unauthorized medications (see section 6.2);
  • The volunteer's incompetence with the study procedures;
  • The volunteer refuses to cooperate or is undisciplined (for example, failure to attend a scheduled visit without warning the researcher and/or loss of communication with the volunteer), or dropped out of observation;
  • For administrative reasons (termination of the study by the Sponsor or regulatory authorities), as well as in case of gross violations of the protocol that may affect the results of the study.

How is the study designed?

Design details.

  • Primary Purpose : Prevention
  • Allocation : Randomized
  • Interventional Model : Parallel Assignment
  • Masking : Double

Number of Arms

Arms and interventions, what is the study measuring, primary outcome measures, secondary outcome measures, collaborators and investigators, study record dates, study major dates, study start (actual), primary completion (anticipated), study completion (anticipated), study registration dates, first submitted, first submitted that met qc criteria, first posted (actual), study record updates, last update posted (estimate), last update submitted that met qc criteria, last verified, more information, terms related to this study.

  • Immunobiological medicine
  • Coronavirus infections

Other Study ID Numbers

  • № VKI-D-III-12/21

Drug and device information, study documents

Studies a u.s. fda-regulated drug product, studies a u.s. fda-regulated device product.

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected] . As soon as a change is implemented on clinicaltrials.gov , this will be updated automatically on our website as well.

Clinical Trials on Vaccine

  • Stanford University Recruiting Supporting CHWs as Vaccine Educators: Impact of a Digital Training and Chatbot Intervention on Vaccination in Kenya Vaccine Hesitancy | Vaccine Refusal | Vaccine Knowledge Kenya
  • University of Ottawa Not yet recruiting Education to Improve Pneumococcal Vaccine Uptake Among Older Adults (PROPEL) Pneumococcal Vaccine Uptake | Vaccination Willingness | Pneumococcal Vaccine Knowledge | Pneumococcal Vaccine Attitude Canada
  • Fudan University The University of Hong Kong Not yet recruiting Effectiveness of Vaccine Chatbot on HPV Vaccine Awareness and Vaccination in China HPV Vaccine China
  • National Cancer Institute (NCI) Not yet recruiting Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer Squamous Cell Carcinoma of the Head and Neck | Drug Therapy | Oropharynx | Human Papillomavirus Viruses | Cancer Vaccine United States
  • Leiden University Medical Center Recruiting Fine Needle aSpiration of Lymph nodEs to Study vAccine-induced Immunity (SEA) Vaccine-Preventable Diseases Netherlands
  • University of California, San Francisco Stanford University; Wuqu' Kawoq, Maya Health Alliance Not yet recruiting Culturally and Linguistically Appropriate Vaccine Education (CLAVE) Vaccine Hesitancy Guatemala
  • M.D. Anderson Cancer Center Recruiting Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation Esophageal Cancer | Chemoradiation | Lymphopenia | Pneumococcal Vaccine United States
  • Pfizer Recruiting A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza Influenza | Vaccines | Grippe United States
  • Guangzhou Patronus Biotech Co., Ltd. Yantai Patronus Biotech Co., Ltd. Not yet recruiting Safety and Immunogenicity of Recombinant COVID-19 Trivalent Protein Vaccine (CHO Cell)LYB002V14 in Booster Vaccination SARS-CoV-2 | COVID-19 Vaccine China
  • Michigan State University Arizona State University Not yet recruiting Game-Based Intervention to Promote HPV Vaccination HPV Infection | Vaccine-Preventable Diseases United States

Clinical Trials on Vaccine for intramuscular injection

  • CanSino Biologics Inc. Recruiting A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years Herpes Zoster Canada
  • Pfizer Recruiting A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults Shingles | Human | Herpes Zoster Infection United States
  • University of Washington United States Department of Defense Recruiting Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions United States
  • Clover Biopharmaceuticals AUS Pty Ltd Withdrawn Immunogenicity and Safety Study of SCB-2023 Vaccine as a Booster in Adults COVID-19 Philippines
  • Seventh Medical Center of PLA General Hospital Active, not recruiting Evaluate the Safety and Immunogenicity of Ad5 COVID-19 Vaccines for Booster Use in Children Aged 6-17 Years. COVID-19 China
  • Scancell Ltd Active, not recruiting A First Time in Human Phase 1 Open-Label Study of the COVIDITY Vaccine Administered by Needle-free Injection COVID-19 South Africa
  • Medicago Active, not recruiting Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults SARS-CoV-2 Infection United States, Canada, United Kingdom, Argentina, Brazil, Mexico
  • Chumakov Federal Scientific Center for Research... Completed This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19 Coronavirus Infections | Vaccine Russian Federation
  • National Institute of Allergy and Infectious Diseases... Completed Safety of an HIV DNA Vaccine Given to HIV Uninfected Adults HIV Infections United States
  • National Institute of Allergy and Infectious Diseases... Completed An Investigational Combination Vaccine Given to People Who Are Not Infected With HIV HIV Infections United States

Search Similar Trials

  • Clinical Trials on Vaccine in Ireland
  • Clinical Trials on Vaccine in India
  • Clinical Trials on Vaccine in New Zealand
  • Clinical Trials on Vaccine in Canada
  • Clinical Trials on Vaccine in United States
  • Clinical Trials on Vaccine in Australia
  • Clinical Trials on Vaccine in United Kingdom
  • Clinical Trials on Vaccine in South Africa
  • Clinical Trials on Vaccine in Singapore
  • Clinical Trials on Vaccine in Hong Kong
  • Search All Trials

Sponsors and Collaborators

  • Oppenheimer Family Psychosocial Oncology and Palliative Care Research Grants
  • Assiut University
  • Gregory A. Schmidt
  • National Masan Tuberculosis Hospital
  • University of Leipzig Medical Center
  • AstraZeneca
  • National Bureau of Economic Research, Inc.
  • Assistance Publique - Hôpitaux de Paris
  • Mayo Clinic
  • Toulouse NeuroImaging Center (ToNIC - UMR 1214 Inserm/UPS)
  • Oak Hill Bio Ltd
  • Novartis Pharmaceuticals
  • Cairo University
  • GlaxoSmithKline
  • Adai Technology (Beijing) Co., Ltd.
  • Tissue Genesis
  • M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
  • View Full List

Medical Conditions

  • Schistosomiasis Haematobia
  • Breast Cancer
  • Prevention Pelvic Muscle Dysfunction
  • Supracristal Ventricular Septal Defect
  • Using Copolamine Butylbromide in Probe-based Confocal Laser Endomicroscopy for Gastroendoscopy Examination
  • Sickle Cell β+ or β0 Thalassemia
  • Per-operation Complications
  • Hypertension
  • HIV Infections
  • Coronary Artery Disease
  • S. Aureus Transmission
  • Cholesterol Embolism
  • Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
  • Stage IIIA Intraocular Melanoma
  • Prostate Cancer

Drug Interventions

  • Cyclophosphamide
  • Normal saline
  • Carboplatin
  • Azadirachta indica
  • Buprenorphine hydrochloride marketed sublingual tablet (Subutex)
  • Bevacizumab
  • Metformin hydrochloride
  • Capecitabine
  • R-CHOP + acalabrutinib
  • Gadoxetate Sodium
  • Dexamethasone
  • Gemcitabine
  • Comparator: timolol maleate

CROs by country

  • Contract Research Organizations in Albania
  • Contract Research Organizations in Bahrain
  • Contract Research Organizations in Benin
  • Contract Research Organizations in Guinea
  • Contract Research Organizations in Hong Kong
  • Contract Research Organizations in Ireland
  • Contract Research Organizations in Japan
  • Contract Research Organizations in Mali
  • Contract Research Organizations in Moldova
  • Contract Research Organizations in Nigeria
  • Contract Research Organizations in Saudi Arabia
  • Contract Research Organizations in Türkiye
  • Contract Research Organizations in Ukraine
  • CRO list by country

CROs in Guinea

  • All CROs in Guinea
  • Alphabetic (A-Z)
  • By Category

Rare Diseases

Dietary supplements, sponsor/collaborators.

medical research journal via medica

Study record managers: refer to the Data Element Definitions if submitting registration or results information.

Search for terms

ClinicalTrials.gov

  • Advanced Search
  • See Studies by Topic
  • See Studies on Map
  • How to Search
  • How to Use Search Results
  • How to Find Results of Studies
  • How to Read a Study Record

About Studies Menu

  • Learn About Studies
  • Other Sites About Studies
  • Glossary of Common Site Terms

Submit Studies Menu

  • Submit Studies to ClinicalTrials.gov PRS
  • Why Should I Register and Submit Results?
  • FDAAA 801 and the Final Rule
  • How to Apply for a PRS Account
  • How to Register Your Study
  • How to Edit Your Study Record
  • How to Submit Your Results
  • Frequently Asked Questions
  • Support Materials
  • Training Materials

Resources Menu

  • Selected Publications
  • Clinical Alerts and Advisories
  • Trends, Charts, and Maps
  • Downloading Content for Analysis

About Site Menu

  • ClinicalTrials.gov Background
  • About the Results Database
  • History, Policies, and Laws
  • ClinicalTrials.gov Modernization
  • Media/Press Resources
  • Linking to This Site
  • Terms and Conditions
  • Search Results
  • Study Record Detail

Maximum Saved Studies Reached

Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19 of Children at the Age of 12-17 Years Inclusive"

  • Study Details
  • Tabular View
  • No Results Posted

sections

Recruitment of volunteers will be competitive. A maximum of 450 children aged 12 to 17 years inclusive will be screened in the study, of which it is planned to include and randomize 300 children who meet the criteria for inclusion in the study and do not have non-inclusion criteria, data on which will be used for subsequent safety and immunogenicity analysis.

Group 1 - 150 volunteers who will be vaccinated with the Nobivac vaccine twice with an interval of 21 days intramuscularly.

Group 2 - 150 volunteers who will receive a placebo twice with an interval of 21 days intramuscularly.

In case of withdrawal of volunteers from the study, their replacement is not provided.

medical research journal via medica

Inclusion Criteria:

  • Volunteers must meet the following inclusion criteria:

Type of participants • Healthy volunteers.

Age at the time of signing the Informed Consent

• from 12 to 17 years inclusive (12 years 0 months 0 days - 17 years 11 months 30 days).

Paul • Male or female.

Reproductive characteristics

  • For girls with a history of mensis - a negative pregnancy test and consent to adhere to adequate methods of contraception (use of contraceptives within a month after the second vaccination). Girls should use methods of contraception with a reliability of more than 90% (cervical caps with spermicide, diaphragms with spermicide, condoms, intrauterine spirals).
  • For young men capable of conception - consent to adhere to adequate methods of contraception (use of contraceptives within a month after the second vaccination). Young men and their sexual partners should use methods of contraception with a reliability of more than 90% (cervical caps with spermicide, diaphragms with spermicide, condoms, intrauterine spirals).

Research procedures

  • Written Informed consent of a volunteer (14 years and older) and one of the parents to participate in a clinical trial.
  • Volunteers who are able to fulfill Protocol requirements (i.e. answer phone calls, fill out a Self-observation Diary, come to control visits).

Non-inclusion criteria:

  • Volunteers cannot be included in the study if any of the following criteria are present:

SARS-CoV-2 infection

  • A case of established COVID-19 disease confirmed by PCR and/or ELISA in the last 6 months.
  • History of contacts with confirmed or suspected cases of SARS-CoV-2 infection within 14 days prior to vaccination.
  • Positive IgM or IgG to SARS-CoV-2 detected on Screening.
  • Positive PCR test for SARS-CoV-2 at Screening / before vaccination.

Diseases or medical conditions

  • Serious post-vaccination reaction (temperature above 40 C, hyperemia or edema more than 8 cm in diameter) or complication (collapse or shock-like condition that developed within 48 hours after vaccination; convulsions, accompanied or not accompanied by a feverish state) to any previous vaccination.
  • Burdened allergic history (anaphylactic shock, Quincke's edema, polymorphic exudative eczema, serum sickness in the anamnesis, hypersensitivity or allergic reactions to the introduction of any vaccines in the anamnesis, known allergic reactions to vaccine components, etc.).
  • Guillain-Barre syndrome (acute polyradiculitis) in the anamnesis.
  • The axillary temperature at the time of vaccination is more than 37.0 ° C.
  • Positive blood test for HIV, syphilis, hepatitis B/C.
  • Acute infectious diseases (recovery earl

Exclusion Criteria:

- • Withdrawal of Informed consent by a volunteer and/or a parent of a volunteer;

  • The volunteer was included in violation of the inclusion/non-inclusion criteria of the Protocol;
  • Availability of inclusion/non-inclusion criteria before vaccination;
  • Any condition of a volunteer that requires, in the reasoned opinion of a medical researcher, the withdrawal of a volunteer from the study;
  • The established fact of pregnancy before the second vaccination;
  • Taking unauthorized medications (see section 6.2);
  • The volunteer's incompetence with the study procedures;
  • The volunteer refuses to cooperate or is undisciplined (for example, failure to attend a scheduled visit without warning the researcher and/or loss of communication with the volunteer), or dropped out of observation;
  • For administrative reasons (termination of the study by the Sponsor or regulatory authorities), as well as in case of gross violations of the protocol that may affect the results of the study.
  • For Patients and Families
  • For Researchers
  • For Study Record Managers
  • Customer Support
  • Accessibility
  • Viewers and Players
  • Freedom of Information Act
  • HHS Vulnerability Disclosure
  • U.S. National Library of Medicine
  • U.S. National Institutes of Health
  • U.S. Department of Health and Human Services

Developing ash-free high-strength spherical carbon catalyst supports

  • Domestic Catalysts
  • Published: 28 June 2013
  • Volume 5 , pages 156–163, ( 2013 )

Cite this article

  • V. V. Gur’yanov 1 ,
  • V. M. Mukhin 1 &
  • A. A. Kurilkin 1  

48 Accesses

Explore all metrics

The possibility of using furfurol for the production of ash-free high-strength active carbons with spheroidal particles as adsorbents and catalyst supports is substantiated. A single-stage process that incorporates the resinification of furfurol, the molding of a spherical product, and its hardening while allowing the process cycle time and the cost of equipment to be reduced is developed. Derivatographic, X-ray diffraction, mercury porometric, and adsorption studies of the carbonization of the molded spherical product are performed to characterize the development of the primary and porous structures of carbon residues. Ash-free active carbons with spheroidal particles, a full volume of sorbing micro- and mesopores (up to 1.50 cm 3 /g), and a uniquely high mechanical strength (its abrasion rate is three orders of magnitude lower than that of industrial active carbons) are obtained via the vapor-gas activation of a carbonized product. The obtained active carbons are superior to all known foreign and domestic analogues and are promising for the production of catalysts that operate under severe regimes, i.e., in moving and fluidized beds.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price includes VAT (Russian Federation)

Instant access to the full article PDF.

Rent this article via DeepDyve

Institutional subscriptions

Burushkina, T.N., Zh. Ross. Khim. O-va im. D.I. Mendeleeva , 1995, vol. 39, no. 6, p. 122.

CAS   Google Scholar  

Kryazhev, Yu. G., Abstract of Papers, Materialy XII vserossiiskogo simpoziuma s uchastiem inostrannykh uchenykh “Aktual’nye problemy teorii adsorptsii, poristosti i adsorptsionnoi selektivnosti” (Proc. of XII th All-Russia Symposium with the Participation of Foreign Scientists “Urgent Problems of the Theory of Adsorption, Porosity, and Adsorption Selectivity”), Moscow, 2008, p. 69.

Google Scholar  

Kartel’, N.T., in Adsorbtsiya, adsorbenty i adsorbtsionnye protsessy v nanoporistykh materialakh (Adsorption, Adsorbents, and Adsorption Processes in Nanoporous Materials), Tsivadze, A.Yu., Ed., Moscow: Granitsa, 2011, p. 381.

RF Patent 2026813, 1993.

RF Patent 2257343, 2003.

RF Patent 2301701, 2006.

Dubinin, M.M., Zaverina, E.D., Ivanova, L.S., Kaverov, A.T., and Kasatochkin, V.I., Rus. Chem. Bull. , 1961, vol. 10, no. 1, p. 14.

Article   Google Scholar  

Usenbaev, K. and Zhumalieva, K., Rentgenograficheskoe issledovanie struktury i termicheskikh preobrazovanii amorfnykh uglerodov (X-ray Study of the Structure and Thermal Transformations of Amorphous Carbons), Frunze: Mektep, 1976.

Gur’yanova, L.N. and Gur’yanov, V.V., Zh. Fiz. Khim. , 1984, vol. 58, no. 6, p. 1459; 1989, vol. 63, no. 1, p. 161; 1989, vol. 63, no. 2, p. 426; 1989, vol. 63, no. 3, p. 683.

Guryanov, V.V., Petukhova, G.A., and Dubinina, L.A., Prot. Metal. Phys. Chem. Surf. , 2010, vol. 46, no. 2, p. 191.

Article   CAS   Google Scholar  

Guryanov, V.V., Dubinin, M.M., and Misin, M.S., Zh. Fiz. Khim. , 1975, vol. 49, no. 9, p. 2374.

Gur’yanov, V.V., Petukhova, G.A., and Polyakov, N.S., Rus. Chem. Bull. , 2001, vol. 50, no. 6, p. 974.

Dubinin, M.M., Carbon , 1989, vol. 27, no. 3, p. 457.

Belyaev, N.M., Soprotivlenie materialov (Strength of Materials), Moscow: Nauka, 1976.

Temkin, I.V., Proizvodstvo elektrougol’nykh izdelii (Production of Electrocarbon Articles), Moscow: Vysshaya shkola, 1980.

Download references

Author information

Authors and affiliations.

OAO Elektrostal’ Research and Production Association Neorganika, Elektrostal’, Moscow oblast, 144001, Russia

V. V. Gur’yanov, V. M. Mukhin & A. A. Kurilkin

You can also search for this author in PubMed   Google Scholar

Additional information

Original Russian Text © V.V. Gur’yanov, V.M. Mukhin, A.A. Kurilkin, 2013, published in Kataliz v Promyshlennosti.

Rights and permissions

Reprints and permissions

About this article

Gur’yanov, V.V., Mukhin, V.M. & Kurilkin, A.A. Developing ash-free high-strength spherical carbon catalyst supports. Catal. Ind. 5 , 156–163 (2013). https://doi.org/10.1134/S2070050413020062

Download citation

Received : 08 December 2011

Published : 28 June 2013

Issue Date : April 2013

DOI : https://doi.org/10.1134/S2070050413020062

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

  • carbon adsorbent
  • porous structure
  • polymerization
  • Find a journal
  • Publish with us
  • Track your research

IMAGES

  1. Via Medica Journals

    medical research journal via medica

  2. Via Medica Journals

    medical research journal via medica

  3. Via Medica Journals

    medical research journal via medica

  4. Ophthalmology Journal Template

    medical research journal via medica

  5. Via Medica Journals

    medical research journal via medica

  6. Via Medica Journals

    medical research journal via medica

VIDEO

  1. Medical professional's biggest problem? Same as Finance professionals?

  2. Day in the life

COMMENTS

  1. Medical Research Journal

    Medical Research Journal (previously Folia Medica Copernicana) is an open access journal of strictly scientific character.

  2. Via Medica Journals

    Since 1993 Via Medica has been publishing journals in various fields of medicine, both clinical and experimental. Nowadays it is more than 40 titles, which include scientific journals published in English and addressed to professionals worldwide.

  3. MEDICAL RESEARCH JOURNAL

    Medical Research Journal (previously Folia Medica Copernicana, ISSN 2300-5432) is a journal under auspices of Collegium Medicum, Nicolaus Copernicus University in Torun, Poland; Cardinal Stefan Wyszynski University in Warsaw, Poland and Section of Nursing and Medical Technology of the Polish Cardiac Society.

  4. MEDICAL RESEARCH JOURNAL

    Medical Research Journal (previously Folia Medica Copernicana, ISSN 2300-5432) is a journal under auspices of Collegium Medicum, Nicolaus Copernicus University in Torun, Poland; Cardinal Stefan Wyszynski University in Warsaw, Poland and Section of Nursing and Medical Technology of the Polish Cardiac Society.

  5. MEDICAL RESEARCH JOURNAL

    Medical Research Journal (previously Folia Medica Copernicana, ISSN 2300-5432) is a journal under auspices of Collegium Medicum, Nicolaus Copernicus University. The journal is published in English four times per year in electronic form.

  6. Journals

    For over 25 years, we have specialized in publishing magazines in various fields of clinical and experimental medicine. Currently, the list covers more than 40 titles and includes: specialized scientific journals, published in English and addressed to international community,

  7. MEDICAL RESEARCH JOURNAL

    Medical Research Journal (previously Folia Medica Copernicana, ISSN 2300-5432) is a journal under auspices of Collegium Medicum, Nicolaus Copernicus University and Cardinal Wyszyński University in Warsaw. The journal is published in English four times per year in electronic form.

  8. PubMed

    PubMed is a comprehensive database of biomedical literature from various sources, including MEDLINE, life science journals, and online books. You can search for citations, access full text content, and explore topics related to health, medicine, and biology. PubMed also provides advanced search options and tools for researchers and clinicians.

  9. Via Medica

    Via Medica. https://journals.viamedica.pl/ Download this publisher's e-journal holdings (xlsx) ... Medical Research Journal 2451-2591, 2451-4101 ... organization helping the academic community use digital technologies to preserve the scholarly record and to advance research and teaching in sustainable ways.

  10. The New England Journal of Medicine: Research & Review Articles on

    The New England Journal of Medicine: Research & Review Articles on Disease & Clinical Practice Original Article International Stroke Conference Tenecteplase for Stroke at 4.5 to 24 Hours G.W....

  11. Medical Research Journal Template

    Medical Research Journal Template - Via Medica Get formatted submissions to Via Medica guidelines. Download output in Ms-Word and LaTeX. Check for Plagiarism via Turnitin. Perform Grammar Check & more. Recent searches Sign up Discover Write For Publishers Menu Log in Sign Up Discover Papers Authors Institutions Topics Journals Conferences Questions

  12. Via Medica

    Compliance for medical journals in PubMed database. SciELO XML. Generate standardized XML for SciELO indexed journals. SciSpace / Formats / Via Medica. Via Medica. Get your research paper 100% compliant with Via Medica Author guidelines. Choose any Journal below to get started.

  13. Home page

    European Journal of Medical Research publishes high quality research and reviews and aims to ensure that the results of all well-conducted research are published, regardless of their outcome. Celebrating 10 Years at BMC!

  14. Journal of International Medical Research: Sage Journals

    First published Jan 24, 2024 Therapeutic changes of systemic lupus erythematosus (SLE) patients in pregnancy and feto-maternal outcomes: a retrospective cohort study Naser Al-Husban Diala Walid Abu-Hassan Ro'ya Ali Abu Saleem [...] View all Open Access Research article First published Jan 24, 2024

  15. Using ChatGPT in Medical Research: Current Status and Future Directions

    This review summarizes the use of ChatGPT in medical research. Currently, this AI is primarily used in drug development, improving medical reports, providing treatment and medical information, writing literature reviews on health-related topics, improving research conduct, data analysis, and personalizing medicine.

  16. Current Medical Research and Opinion

    Journal metrics Editorial board. Current Medical Research and Opinion (CMRO) is a MEDLINE-indexed, international journal that publishes research focused on new and existing drugs and therapies, best practices in patient care, developments in diagnostic medicine and medical technology, and innovations in medical and scientific publishing.

  17. Statistical Methods in Medical Research: Sage Journals

    Statistical Methods in Medical Research is a highly ranked, peer reviewed scholarly journal and is the leading vehicle for articles in all the main areas of medical statistics and therefore an essential reference for all medical statisticians. It is … | View full journal description

  18. Medica Journal

    -Our Vision- To be a distinctive, preeminent research-intensive medical study platform, transforming health through discovery, lifelong learning, and patient-centered health care. Pre-Medicine It makes sense to assume that every pre-med student is destined to become a doctor, but that's not always the case.

  19. Vaccine for intramuscular injection in Vaccine

    Research procedures Written Informed consent of a volunteer (14 years and older) and one of the parents to participate in a clinical trial. Volunteers who are able to fulfill Protocol requirements (i.e. answer phone calls, fill out a Self-observation Diary, come to control visits).

  20. Double-blind, Placebo-controlled, Randomized Study of the Tolerability

    Recruitment of volunteers will be competitive. A maximum of 450 children aged 12 to 17 years inclusive will be screened in the study, of which it is planned to include and randomize 300 children who meet the criteria for inclusion in the study and do not have non-inclusion criteria, data on which will be used for subsequent safety and immunogenicity analysis.

  21. Directory of Open Access Journals

    Неврология, нейропсихиатрия, психосоматика (Nov 2016) . Prevention of cerebrovascular diseases and cognitive impairment in psychiatric and neurological practice: A literature review

  22. Developing ash-free high-strength spherical carbon catalyst supports

    Abstract. The possibility of using furfurol for the production of ash-free high-strength active carbons with spheroidal particles as adsorbents and catalyst supports is substantiated. A single-stage process that incorporates the resinification of furfurol, the molding of a spherical product, and its hardening while allowing the process cycle ...